ARTICLE | Clinical News
Sym004: Phase IIb started
August 18, 2014 7:00 AM UTC
Symphogen said Merck began an open-label, international Phase IIb trial to compare IV Sym004 vs. investigator’s choice of best supportive care (BSC) in about 240 patients with mCRC and acquired resist...